Dazukibart is effective in reducing disease activity in adults with refractory dermatomyositis
1. CDASI-A score at 12 weeks was significantly lower in dazukibart 600 mg versus placebo, suggesting reduced morbidity. 2. Treatment-related ...
1. CDASI-A score at 12 weeks was significantly lower in dazukibart 600 mg versus placebo, suggesting reduced morbidity. 2. Treatment-related ...
1. Patients with dermatomyositis treated with intravenous immune globulin (IVIG) were more likely to see improvement in their disease severity ...
1. Patients with dermatomyositis treated with intravenous immune globulin (IVIG) were more likely to see improvement in their disease severity ...
1. In adults with dermatomyositis (DM), calcinosis was positively associated with longer disease duration, fingertip ulcers, and NXP-2 autoantibodies and ...
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.
© 2021 2 Minute Medicine, Inc. - Physician-written medical news.
© 2021 2 Minute Medicine, Inc. - Physician-written medical news.